Compass Therapeutics, Inc.
CMPX
$1.97
$0.105.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 60.00% | 44.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.83% | 13.74% | |||
| Operating Income | -12.83% | -13.74% | |||
| Income Before Tax | -16.55% | -10.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.55% | -10.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.55% | -10.22% | |||
| EBIT | -12.83% | -13.74% | |||
| EBITDA | -12.86% | -13.77% | |||
| EPS Basic | -15.65% | -0.59% | |||
| Normalized Basic EPS | -15.63% | -0.57% | |||
| EPS Diluted | -15.65% | -0.59% | |||
| Normalized Diluted EPS | -15.63% | -0.57% | |||
| Average Basic Shares Outstanding | 0.84% | 9.52% | |||
| Average Diluted Shares Outstanding | 0.84% | 9.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||